ArticleAnnals of surgical oncology2026
Outpatient Mastectomy with Reconstruction at Ambulatory Surgery Centers.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- When immunotherapy hurts: neoadjuvant PD-1 inhibitors increase opioid use after mastectomy with reconstruction.Breast cancer research and treatment · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstarct
backgroundWhile ambulatory surgery centers (ASCs) are increasingly utilized for outpatient surgery for cost savings and resource efficiency, data comparing outcomes and costs of same-day mastectomy (SDM) with reconstruction at ASCs versus hospital outpatient departments (HOPDs) remain limited. We aimed to identify predictors of overnight admission following SDM with immediate implant/tissue expander reconstruction, and evaluate its safety, feasibility, and cost-efficacy at ASCs versus HOPDs. PATIENTS AND
methodsWe performed a retrospective review of women undergoing mastectomy with immediate implant/tissue expander reconstruction from January 2023 to June 2024 at two HOPDs and two ASCs. Patient characteristics, operative metrics, postoperative complications, and predictors of overnight admission were analyzed. Cost analyses utilized Medicare outpatient procedure facility fees for comparison.
resultsA total of 492 of 559 patients (88.0%) underwent same-day discharge, including all patients at ASCs. Significant predictors of any overnight admission included age > 65 (OR = 2.482, p = 0.027), living > 30 miles from the hospital (OR = 2.162, p = 0.005), bilateral surgery (OR = 2.435, p = 0.016), and afternoon PACU arrival (OR = 2.005, p = 0.028). Predictors of unplanned overnight admission were increased distance from the hospital (OR = 2.316 (1.110-4.921)), bilateral surgery (OR = 3.020 (1.110-10.613)), and afternoon PACU arrival (OR = 2.698 (1.144-7.449)). ASC patients experienced shorter postoperative stays and equivalent postoperative complications. Cost analysis demonstrated that performing identical procedures at ASCs significantly reduced facility fees (p < 0.001), yielding estimated savings of $1,785,496 (61.2%) per 99 patients compared with HOPDs.
conclusionsFor appropriately selected patients, SDM with reconstruction at ASCs is safe, feasible, and associated with substantial cost savings. These findings support expanded use of ASCs to optimize resource utilization without compromising patient outcomes.
Indexed as
Identifiers
41708932What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.